CytomX Therapeutics (CTMX) Cash & Equivalents (2014 - 2026)

CytomX Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $28.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 39.44% year-over-year to $28.8 million; the trailing twelve-month figure through Mar 2026 stood at $28.8 million (down 39.44% YoY), and the FY2025 full-year result was $12.7 million, down 66.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $28.8 million, up from $12.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $193.6 million in Q4 2022, with the low at $12.7 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $62.9 million across 5 years, with a median of $43.2 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 91.13% — and 2024, when it soared 121.61%.
• CytomX Therapeutics' Cash & Equivalents stood at $193.6 million in 2022, then sank by 91.13% to $17.2 million in 2023, then soared by 121.61% to $38.1 million in 2024, then slumped by 66.71% to $12.7 million in 2025, then surged by 127.58% to $28.8 million in 2026.
• The last three Cash & Equivalents figures came in at $28.8 million (Q1 2026), $12.7 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.